Lupin Buys Shionogi Brands As Japan Market Opens To Indian Firms

Kyowa, the Japanese arm of Indian major Lupin, is buying a basket of mature products including CNS drugs Rhythmy and Resmit from Shionogi. As innovator companies seek to shed older products in Japan, generic firms, especially Indian ones, are taking advantage to expand in the world's second largest pharmaceutical market.

Japan and India

Lupin Ltd., India's third largest drug firm by sales, on Aug. 2, said that its Japanese arm Kyowa Pharmaceutical Industry Co. Ltd. is acquiring 21 long-listed products (off-patent branded medicines) from Shionogi & Co. Ltd. , for 15.4bn yen ($150m).

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Deals

More from Business